stoxline Quote Chart Rank Option Currency Glossary
Mereo BioPharma Group plc (MREO)
3.865  -0.025 (-0.64%)    07-18 15:51
Open: 3.92
High: 3.9405
Volume: 597,729
Pre. Close: 3.89
Low: 3.8008
Market Cap: 542(M)
Technical analysis
2024-07-18 3:21:51 PM
Short term     
Mid term     
Targets 6-month :  4.7 1-year :  5.25
Resists First :  4.02 Second :  4.5
Pivot price 3.77
Supports First :  3.25 Second :  2.71
MAs MA(5) :  4.02 MA(20) :  3.76
MA(100) :  3.35 MA(250) :  2.59
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  61.2 D(3) :  73.1
RSI RSI(14): 53.1
52-week High :  4.5 Low :  1.07
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MREO ] has closed below upper band by 43.0%. Bollinger Bands are 5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.08 - 4.1 4.1 - 4.12
Low: 3.77 - 3.8 3.8 - 3.82
Close: 3.85 - 3.9 3.9 - 3.93
Company Description

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Headline News

Tue, 16 Jul 2024
Mereo BioPharma Group (NASDAQ:MREO) Trading Down 3.1% - MarketBeat

Mon, 15 Jul 2024
Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat -

Sun, 30 Jun 2024
Mereo BioPharma: Positioned For Potential Breakthroughs (MREO) - Seeking Alpha

Sat, 29 Jun 2024
Charles Sermon Sells 14,202 Shares of Mereo BioPharma Group plc (NASDAQ:MREO) Stock - Defense World

Thu, 27 Jun 2024
Mereo BioPharma's CEO Denise Scots-Knight sells over $460k in company stock -

Fri, 14 Jun 2024
MREO - Mereo BioPharma Group plc Latest Stock News & Market Updates - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 153 (M)
Shares Float 457 (M)
Held by Insiders 0.5 (%)
Held by Institutions 56.2 (%)
Shares Short 2,350 (K)
Shares Short P.Month 2,210 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin -263.5 %
Operating Margin -256.5 %
Return on Assets (ttm) -20.6 %
Return on Equity (ttm) -56 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.06
EBITDA (p.s.) -0.17
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -25.6
PEG Ratio 0
Price to Book value 12.38
Price to Sales 58.67
Price to Cash Flow -29.52
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android